{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:32:54Z","timestamp":1791113574739,"version":"4.1.0"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.2215\/cjn.01340209","type":"journal-article","created":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T20:59:26Z","timestamp":1252011566000},"page":"1685-1691","source":"Crossref","is-referenced-by-count":26,"title":["Mineralocorticoid Receptor Blockers and Chronic Kidney Disease"],"prefix":"10.2215","volume":"4","author":[{"given":"Gaurav","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth C.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20230601","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"R2-21-20230601","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1681\/ASN.2008111212","article-title":"The case for using albuminuria in staging chronic kidney disease","volume":"20","author":"Gansevoort","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R3-21-20230601","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1681\/ASN.2008070730","article-title":"Combining GFR and albuminuria to classify CKD improves prediction of ESRD","volume":"20","author":"Hallan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R4-21-20230601","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R5-21-20230601","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R6-21-20230601","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"R7-21-20230601","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MNH.0b013e3282f29028","article-title":"Aldosterone and progression of renal disease","volume":"17","author":"Wenzel","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R8-21-20230601","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.amjhyper.2007.09.001","article-title":"Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus","volume":"20","author":"Yoneda","year":"2007","journal-title":"Am J Hypertens"},{"key":"R9-21-20230601","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R10-21-20230601","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R11-21-20230601","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R12-21-20230601","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R13-21-20230601","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"R14-21-20230601","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00109-008-0323-5","article-title":"New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone","volume":"86","author":"Lemarie","year":"2008","journal-title":"J Mol Med"},{"key":"R15-21-20230601","first-page":"134","article-title":"Aldosterone, mineralocorticoid receptors, and vascular inflammation","volume":"16","author":"Fiebeler","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R16-21-20230601","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","article-title":"New aspects of rapid aldosterone signaling","volume":"308","author":"Grossmann","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"R17-21-20230601","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1161\/HYPERTENSIONAHA.108.121269","article-title":"Networking between systemic angiotensin II and cardiac mineralocorticoid receptors","volume":"52","author":"Montezano","year":"2008","journal-title":"Hypertension"},{"key":"R18-21-20230601","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/ATVBAHA.108.168021","article-title":"Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways","volume":"28","author":"Montezano","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R19-21-20230601","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.108.117531","article-title":"Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling","volume":"52","author":"Zhang","year":"2008","journal-title":"Hypertension"},{"key":"R20-21-20230601","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MNH.0b013e3282f56854","article-title":"Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation","volume":"17","author":"Young","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R21-21-20230601","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1210\/en.2006-1691","article-title":"Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling","volume":"148","author":"Stas","year":"2007","journal-title":"Endocrinology"},{"key":"R22-21-20230601","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cvr\/cvn064","article-title":"Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: Possible role of AT1 receptor dimerization","volume":"79","author":"Yamada","year":"2008","journal-title":"Cardiovasc Res"},{"key":"R23-21-20230601","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.steroids.2008.01.013","article-title":"Aldosterone-induced signalling and cation transport in the distal nephron","volume":"73","author":"Thomas","year":"2008","journal-title":"Steroids"},{"key":"R24-21-20230601","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/HYPERTENSIONAHA.108.121954","article-title":"Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation","volume":"53","author":"Wei","year":"2009","journal-title":"Hypertension"},{"key":"R25-21-20230601","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"R26-21-20230601","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1254\/jphs.08R02CR","article-title":"Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury","volume":"108","author":"Kiyomoto","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"R27-21-20230601","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.jrn.2008.10.007","article-title":"Role of sodium intake in the progression of chronic kidney disease","volume":"19","author":"Ritz","year":"2009","journal-title":"J Ren Nutr"},{"key":"R28-21-20230601","first-page":"F635","article-title":"Dietary salt modulates renal production of transforming growth factor-beta in rats","volume":"274","author":"Ying","year":"1998","journal-title":"Am J Physiol"},{"key":"R29-21-20230601","first-page":"289","article-title":"Serum aldosterone and protein-binding variables in Yanomama Indians: A no-salt culture as compared to partially acculturated Guaymi Indians","volume":"3","author":"Nowaczynski","year":"1985","journal-title":"Clin Physiol Biochem"},{"key":"R30-21-20230601","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/01.CIR.52.1.146","article-title":"Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a \u201cno-salt\u201d culture","volume":"52","author":"Oliver","year":"1975","journal-title":"Circulation"},{"key":"R31-21-20230601","doi-asserted-by":"crossref","first-page":"F1178","DOI":"10.1152\/ajprenal.00386.2003","article-title":"Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet","volume":"286","author":"Wang","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"R32-21-20230601","first-page":"177","article-title":"Salt and its effect on blood pressure and target organ damage: New pieces in an old puzzle","volume":"22","author":"Titze","year":"2009","journal-title":"J Nephrol"},{"key":"R33-21-20230601","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/HYPERTENSIONAHA.107.095489","article-title":"Aldosterone and vascular inflammation","volume":"51","author":"Brown","year":"2008","journal-title":"Hypertension"},{"key":"R34-21-20230601","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","article-title":"Actions of aldosterone in the cardiovascular system: The good, the bad, and the ugly?","volume":"458","author":"Gekle","year":"2009","journal-title":"Pflugers Arch"},{"key":"R36-21-20230601","first-page":"e154","article-title":"ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"R37-21-20230601","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"R38-21-20230601","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1159\/000115291","article-title":"Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease","volume":"28","author":"Agarwal","year":"2008","journal-title":"Am J Nephrol"},{"key":"R39-21-20230601","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"key":"R40-21-20230601","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1681\/ASN.2007040422","article-title":"Age affects outcomes in chronic kidney disease","volume":"18","author":"O'Hare","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R42-21-20230601","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"R43-21-20230601","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14656566.8.5.529","article-title":"Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: Is oral renin inhibition the solution?","volume":"8","author":"Athyros","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R44-21-20230601","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"R45-21-20230601","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"The Lancet"},{"key":"R46-21-20230601","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1751-7176.2009.00110.x","article-title":"Aldosterone excess or escape: Treating resistant hypertension","volume":"11","author":"Ubaid-Girioli","year":"2009","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R47-21-20230601","doi-asserted-by":"crossref","first-page":"R946","DOI":"10.1152\/ajpregu.00402.2006","article-title":"Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker","volume":"292","author":"Ohtani","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R48-21-20230601","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00109-008-0340-4","article-title":"New angiotensins","volume":"86","author":"Varagic","year":"2008","journal-title":"J Mol Med"},{"key":"R49-21-20230601","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/ki.2008.380","article-title":"Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade","volume":"74","author":"Chen","year":"2008","journal-title":"Kidney Int"},{"key":"R50-21-20230601","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/ki.2008.420","article-title":"Candesartan and renal protection: More than blocking angiotensin type 1 receptor?","volume":"74","author":"Macconi","year":"2008","journal-title":"Kidney Int"},{"key":"R51-21-20230601","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrneph.2009.77","article-title":"Proteinuria: Increased angiotensin-receptor blocking is not the first option","volume":"5","author":"Ruggenenti","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"R52-21-20230601","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"Supramaximal dose of candesartan in proteinuric renal disease","volume":"20","author":"Burgess","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R53-21-20230601","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1523-1755.2002.00535.x","article-title":"Effect of high dose ramipril with or without indomethacin on glomerular selectivity","volume":"62","author":"Pisoni","year":"2002","journal-title":"Kidney Int"},{"key":"R54-21-20230601","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R55-21-20230601","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/j.ajkd.2008.11.016","article-title":"Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD?","volume":"53","author":"Berns","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R56-21-20230601","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(08)61212-X","article-title":"Renin-angiotensin blockade and kidney disease","volume":"372","author":"Sarafidis","year":"2008","journal-title":"Lancet"},{"key":"R57-21-20230601","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/sj.ki.5002511","article-title":"Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney","volume":"72","author":"Tylicki","year":"2007","journal-title":"Kidney Int"},{"key":"R58-21-20230601","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejheart.2007.12.006","article-title":"Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added trial","volume":"10","author":"Weir","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"R59-21-20230601","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertens Res"},{"key":"R60-21-20230601","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R61-21-20230601","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11906-009-0022-9","article-title":"Intensified inhibition of renin-angiotensin system: A way to improve renal protection?","volume":"11","author":"Cravedi","year":"2009","journal-title":"Curr Hypertens Rep"},{"key":"R62-21-20230601","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R63-21-20230601","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R64-21-20230601","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"R65-21-20230601","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2008-2660","article-title":"Differential effects of chlorthalidone vs. spironolactone on muscle sympathetic nerve activity in hypertensive patients","volume":"94","author":"Menon","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R68-21-20230601","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"R69-21-20230601","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/pds.1511","article-title":"Study of the use of a spironolactone and angiotensin-converting enzyme inhibitor combination: A population-based analysis","volume":"17","author":"Besancon","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R70-21-20230601","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cardfail.2006.01.003","article-title":"Appropriateness of spironolactone prescribing in heart failure patients: A population-based study","volume":"12","author":"Ko","year":"2006","journal-title":"J Card Fail"},{"key":"R71-21-20230601","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R72-21-20230601","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000210553","article-title":"Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients","volume":"114","author":"Matsumoto","year":"2009","journal-title":"Cardiology"},{"key":"R73-21-20230601","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R74-21-20230601","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/HYPERTENSIONAHA.108.125252","article-title":"Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease","volume":"53","author":"Preston","year":"2009","journal-title":"Hypertension"},{"key":"R75-21-20230601","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000210552","article-title":"The role of aldosterone blockade in end-stage renal disease","volume":"114","author":"Pitt","year":"2009","journal-title":"Cardiology"},{"key":"R76-21-20230601","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"R77-21-20230601","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1291\/hypres.29.211","article-title":"Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection","volume":"29","author":"Sato","year":"2006","journal-title":"Hypertens Res"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-200910000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:38:55Z","timestamp":1786369135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-200910000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01340209","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}